Securing funds for growth investment through business portfolio and cash flow management
First written in FY2021. 3 of 10 entries say "Raised", first in FY2023-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026SoftenedAnnual report
「The Group plans capital expenditures, including new construction and expansion, of ¥338 billion during the one-year period following the current consolidated fiscal year. The breakdown by business segment and an overview of the plan are as follows.」
The company reduced the capital expenditure plan for the following fiscal year from the ¥462 billion disclosed for the previous fiscal year to ¥338 billion. The breakdown includes ¥230 billion for healthcare and ¥52 billion for electronics. - FY2026-H1Healthcare capital expenditure plan updatedAnnual report
「With respect to major facility construction and other projects that were planned as of the end of the previous consolidated fiscal year, the company changed the healthcare segment’s capital expenditure plan during the current interim consolidated accounting period as follows. Healthcare ¥364 billion Expansion of production capacity, manufacturing equipment rationalisation and labour-saving measures, and environmental protection (Note) The amount of the biopharmaceutical CDMO capital expenditure plan was changed owing to higher labour and material costs, among other factors.」
The company updated the healthcare capital expenditure plan for the current fiscal year to ¥364 billion and disclosed changes to the plan for expanding production capacity and other purposes owing to higher labour and material costs, among other factors. - FY2025SoftenedAnnual report
「The Group plans capital expenditures, including new construction and expansion, of ¥462 billion during the one-year period following the current consolidated fiscal year. The breakdown by business segment and an overview of the plan are as follows.」
While the company reduced its capital expenditure plan for the following fiscal year from the ¥510 billion disclosed for the previous fiscal year to ¥462 billion, it carried out ¥532.1 billion in capital expenditures during the current fiscal year. - FY2024RaisedAnnual report
「The Group plans capital expenditures, including new construction and expansion, of ¥510 billion during the one-year period following the current consolidated fiscal year. The breakdown by business segment and an overview of the plan are as follows.」
The company increased its growth investment plan from the ¥480 billion disclosed for the previous fiscal year to ¥510 billion, including a ¥395 billion healthcare plan and a ¥62 billion electronics plan for the following fiscal year. - FY2023RaisedAnnual report
「The Group plans capital expenditures, including new construction and expansion, of ¥480 billion during the one-year period following the current consolidated fiscal year. The breakdown by business segment and an overview of the plan are as follows.」
The company increased its capital expenditure plan from the previous ¥320 billion to ¥480 billion and presented plans including ¥385 billion for healthcare and ¥68 billion for materials. - FY2023-Q3SoftenedAnnual report
「At the end of the current consolidated fiscal year, the plan for the Group’s capital expenditures, including new construction and expansion, during the current consolidated fiscal year was ¥300 billion. However, following, among other factors, a change in the healthcare segment’s planned amount from ¥215 billion to ¥230 billion, the plan was changed to ¥320 billion as of the end of the third quarter of the current consolidated fiscal year.」
The company reduced its capital expenditure plan from the previous quarter’s ¥350 billion overall and ¥260 billion for healthcare to ¥320 billion overall and ¥230 billion for healthcare. - FY2023-Q2RestatedAnnual report
「At the end of the previous consolidated fiscal year, the plan for the Group’s capital expenditures, including new construction and expansion, during the current consolidated fiscal year was ¥300 billion. However, following, among other factors, a change in the healthcare segment’s planned amount from ¥215 billion to ¥260 billion, the plan was changed to ¥350 billion as of the end of the first quarter.」
The company reconfirms the capital expenditure plan of ¥350 billion overall and ¥260 billion for healthcare, as revised in the first quarter. - FY2023-Q1RaisedAnnual report
「At the end of the previous consolidated fiscal year, the plan for the Group’s capital expenditures, including new construction and expansion, during the current consolidated fiscal year was ¥300 billion. However, following, among other factors, a change in the healthcare segment’s planned amount from ¥215 billion to ¥260 billion, the plan was changed to ¥350 billion as of the end of the first quarter of the current consolidated fiscal year.」
The company increased its capital expenditure plan from ¥300 billion to ¥350 billion overall and from ¥215 billion to ¥260 billion for healthcare, expanding the scale of growth investment. - FY2022AdvancedAnnual report
「By strengthening business portfolio management and cash flow management, among other measures, the company will accelerate and strengthen the cycle of securing funding for growth investment and concentrating management resources on priority, new and future-growth businesses. It will thereby advance “accelerating growth in healthcare and high-performance materials and building a robust business foundation capable of sustaining growth.”」
In the first year of VISION2023, the company implemented its resource allocation measures as a cycle of segment restructuring, investment in healthcare and high-performance materials, and cash generation. - FY2021First statedAnnual report
「The company aims to secure funding for growth investment and accelerate and strengthen the cycle of concentrating management resources on priority, new and future-growth businesses by strengthening business portfolio management and cash flow management, among other measures.」
As a means of achieving the new medium-term plan, the company presents, for the first time as a standalone initiative, a management approach that links business replacement and selection with cash generation to strengthen investment in priority, new and future-growth businesses.